Impact of BRAF and RAS mutations on first-line efficacy of FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab: analysis of the FIRE-3 (AIO KRK-0306) study
Stintzing, S., Miller-Phillips, L., Modest, D.P., Fischer von Weikersthal, L., Decker, T., Kiani, A., Vehling-Kaiser, U., Al-Batran, S.-E., Heintges, T., Kahl, C., Seipelt, G., Kullmann, F., Stauch, MVolume:
79
Langue:
english
Journal:
European Journal of Cancer
DOI:
10.1016/j.ejca.2017.03.023
Date:
July, 2017
Fichier:
PDF, 999 KB
english, 2017
File converter
Plus de résultats de recherche
More benefits 
